Effets D'un Bloc Glutéal Postérieur Profond Associé À Un PENG Bloc Dans La Prothèse Totale De Hanche
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 35
- Primary Endpoint
- Sciatic nerve block
Study Overview
Brief Summary
This study aims to evaluate the effectiveness of a posterior hip capsule block performed in addition to a PENG (Pericapsular Nerve Group) block for patients undergoing hip arthroplasty. The primary objective is to assess whether this combined approach provides enhanced perioperative analgesia compared to the standard analgesic protocol or the PENG block alone. Secondary outcomes will focus on opioid consumption, functional recovery, and any potential complications. By targeting both the anterior and posterior innervation pathways around the hip joint, this combined technique could improve patient comfort, decrease opioid requirements, and potentially expedite rehabilitation after hip arthroplasty.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All adults with total hip arthroplasty
Exclusion Criteria
- •Contraindication to regional anesthesia
- •refusal of the injection
Arms & Interventions
DPPG compartment block
Deep posterior post gluteal compartment block with different volume of product 5,10 and 15 ml (local anesthetics such as naropeine 0.35%) to compare the efficiency of the block without sciatic nerve block effect
Intervention: Deep posterior post gluteal nerve block (Procedure)
Outcomes
Primary Outcomes
Sciatic nerve block
Time Frame: From enrollment to the end of treatment at 1 month
number of patients with postoperative sciatic motor or sensitory nerve block collected by clinical examination (test with hot and cold in the sciatic territory and motricity of the feet)
Secondary Outcomes
- Pain postoperative(From enrollment to the end of treatment at 1 MONTH)
- pain 2(From enrollment to the end of treatment at 1 MONTH)
- oPIOID Consumption(From enrollment to the end of treatment at 7 months)
- RAAC(From enrollment to the end of treatment at 1 MONTH)
- Surgical complication(From enrollment to the end of treatment at 1 MONTH)
Investigators
Yoann ELMALEH
Medical Doctor, Anesthesiology and Pain Medicine, Principal Investigator
Quincy Anesthésie